|
|
|
|
Vol. 9, Issue 11, 3071-3083, November 1998
Département de Biologie Cellulaire, Université de Genève Sciences III, CH-1211 Genève 4, Switzerland
Submitted April 21, 1998; Accepted August 19, 1998| |
ABSTRACT |
|---|
|
|
|---|
The heat-shock protein 90 (Hsp90) is a cytosolic molecular
chaperone that is highly abundant even at normal temperature. Specific functions for Hsp90 have been proposed based on the characterization of
its interactions with certain transcription factors and kinases including Raf in vertebrates and flies. We therefore decided to address
the role of Hsp90 for MAP kinase pathways in the budding yeast, an
organism amenable to both genetic and biochemical analyses. We found
that both basal and induced activities of the pheromone-signaling pathway depend on Hsp90. Signaling is defective in strains expressing low levels or point mutants of yeast Hsp90 (Hsp82), or human Hsp90
instead of the wild-type protein. Ste11, a yeast equivalent of Raf,
forms complexes with wild-type Hsp90 and depends on Hsp90 function for
accumulation. For budding yeast, Ste11 represents the first identified
endogenous "substrate" of Hsp90. Moreover, Hsp90 functions in
steroid receptor and pheromone signaling can be genetically separated
as the Hsp82 point mutant T525I and the human Hsp90
are specifically
defective for the former and the latter, respectively. These findings
further corroborate the view that molecular chaperones must also be
considered as transient or stable components of signal transduction pathways.
| |
INTRODUCTION |
|---|
|
|
|---|
The 90-kDa heat-shock protein (Hsp90)1 (for
reviews, see Jakob and Buchner, 1994
; Csermely et al., 1998
)
is an ubiquitous and abundantly expressed cytosolic protein even at
normal temperature. It is highly conserved from bacteria to mammals.
Two genes encode closely related isoforms in mammals as well as in the
budding yeast Saccharomyces cerevisiae. Deletion experiments
in yeast have shown that the expression of at least one of the two
Hsp90 isoforms, either Hsp82 or Hsc82, is essential for viability
(Borkovich et al., 1989
). Similarly, many mutant alleles of
the Drosophila HSP90 homolog, HSP83, are
embryonic lethals over a deficiency of the locus (van der Straten
et al., 1997
), whereas the Escherichia coli
homolog of Hsp90, HtpG, appears to be dispensable (Bardwell and Craig,
1988
). Hsp90 can act as a molecular chaperone in vitro to promote
refolding of denatured proteins (Wiech et al., 1992
; Yonehara et al., 1996
; see also Shaknovich et
al., 1992
; Shue and Kohtz, 1994
), to hold denatured proteins in a
folding-competent state for other chaperones (Freeman and Morimoto,
1996
; Yonehara et al., 1996
) and to prevent protein
unfolding and aggregation (Miyata and Yahara, 1992
; Jakob et
al., 1995a
, 1995b
; Yonehara et al., 1996
).
The interaction of Hsp90 with steroid receptors, which can be thought
of as a signal transduction complex, has been the most extensively
investigated. A variety of in vitro and in vivo studies have revealed
that steroid receptors are complexed with Hsp90 and several other
proteins in the absence of hormone (for review, see Pratt and Toft,
1997
). Upon ligand binding, the hormone binding domain (HBD) undergoes
a conformational change that results in the release of Hsp90 and the
concomitant activation of the steroid receptor. Steroid receptors and
many heterologous proteins fused to the HBD are maintained inactive in
the absence of hormone. We have therefore hypothesized that the
hormone-reversible inactivation function of the HBD is mediated by
Hsp90, possibly by steric hindrance (Picard, 1993
, 1994
). Further
insights into the role of Hsp90 in the regulation of this particular
signal transduction pathway come from studies made in yeast (reviewed
in Picard, 1998
). Vertebrate steroid receptors expressed in yeast
strains with a low level (Picard et al., 1990
; see also
Holley and Yamamoto, 1995
) or specific point mutants of Hsp82 (Bohen
and Yamamoto, 1993
; Bohen, 1995
; Nathan and Lindquist, 1995
; Fang
et al., 1996
) show a defective hormonal response that is due
to a decrease in the ligand-binding affinity (Bohen, 1995
; Fang
et al., 1996
). Thus, Hsp90 may have a dual role: it ensures
that receptors are kept inactive in the absence of hormone and helps
them to respond specifically and efficiently to ligand. This view is
also corroborated by pharmacological in vivo experiments with
geldanamycin (Whitesell et al., 1994
), a compound that
interferes with certain Hsp90 functions such as the proper maturation
of steroid receptor-Hsp90 complexes (Smith et al., 1995
;
Whitesell and Cook, 1996
; Bamberger et al., 1997
; Czar
et al., 1997
; Segnitz and Gehring, 1997
).
There is ample evidence for a role of Hsp90 in regulating the activity
of several other signaling pathways, such as the xenobiotic response
mediated by the dioxin receptor (see for example Pongratz et
al., 1992
; Carver et al., 1994
; McGuire et
al., 1994
; Antonsson et al., 1995
; Coumailleau et
al., 1995
; Whitelaw et al., 1995
). Interaction of the
dioxin receptor with Hsp90 is essential for ligand binding and for
acquiring a DNA-binding conformation. Activation of the dioxin receptor
depends on the release of Hsp90 upon ligand binding and
heterodimerization with Arnt. A functional dependence on, and a direct
interaction with, Hsp90 has also been described for kinases such as the
fission yeast Wee1 (Aligue et al., 1994
), the vertebrate
v-Src (Schuh et al., 1985
; Xu and Lindquist, 1993
; Nathan
and Lindquist, 1995
), and the related kinase Lck (Hartson et
al., 1996
).
Hsp90 may also be required for growth factor signaling. 1) Raf-1, a
serine/threonine kinase involved in mitogenic signal transduction in
vertebrates, exists in a geldanamycin-sensitive heterocomplex with
Hsp90 (Stancato et al., 1993
, 1994
; Lovric et
al., 1994
; Wartmann and Davis, 1994
; Schulte et al.,
1995
, 1996
; Stancato et al., 1997
). 2) Mutations in
Drosophila HSP83 reduce signaling by the torso (Doyle
and Bishop, 1993
) and sevenless receptors (Cutforth and Rubin, 1994
;
van der Straten et al., 1997
), which may be due, at least in
part, to a requirement for Hsp90 for Raf function (van der Straten
et al., 1997
). 3) The insulin receptor binds Hsp90, and
antibodies to Hsp90 interfere with insulin signaling (Takata et
al., 1997
).
Comparable MAPK pathways also exist in yeast where they regulate the
pheromone response, invasive growth, pseudohyphal development, osmoregulation, cell wall integrity, and sporulation (for reviews, see
Herskowitz, 1995
; Levin and Errede, 1995
; Schultz et al., 1995
; Leberer et al., 1997
). The pheromone-signaling pathway
has received a lot of attention over the past few years. Binding of the
mating pheromones to transmembrane receptors elicits a series of events
including the sequential activation of the kinases Ste11, Ste7, and
Fus3, leading to morphological changes, a cell cycle arrest in G1, and
the expression of specific genes required for mating. The kinase Ste11
from S. cerevisiae occupies a position analogous to that of
Raf. This prompted us to test genetically whether Hsp90 plays a role in
the pheromone pathway.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Plasmids
Hsp90 plasmids.
Wild-type Hsp82 (Hsp82 wt), Hsp82 G313N, and
Hsp82 T525I were expressed from plasmids pTCA/Hsp82, pTCA/Hsp82 G313N,
and pTCA/Hsp82 T525I, respectively (Bohen, 1995
), or various
derivatives thereof with other auxotrophic markers. Unless indicated,
the strong constitutive promoter from the glyceraldehyde-3-phosphate
dehydrogenase (GPD) gene TDH3 was used to drive
expression. Plasmid pHCA/Hsp82 is the HIS3 version of
pTCA/Hsp82 obtained by substituting the backbone of shuttle vector
pRS313 for that of pRS314 (Sikorski and Hieter, 1989
). Plasmid
p2U/Hsp82, a 2µ-URA3 expression vector for Hsp82 has
been described previously (Louvion et al., 1996
).
expressing human Hsp90
was constructed as
follows. The coding sequence for human Hsp90
was excised as a
SnaBI-SalI fragment from pKN1-3 (Rebbe et
al., 1987
sequence was fused to the GPD promoter in
shuttle vector pRS304 (Sikorski and Hieter, 1989
is the HIS3 version based on
expression vector p2HG (Picard et al., 1990
are identical to
plasmids p2HG/Hsp82 (Louvion et al., 1996
, respectively,
except that they lack an internal HindIII fragment of the
HIS3 marker. Thus, rather than an auxotrophic marker it is
the Hsp90 function itself that provides the selectable marker for these plasmids.
Plasmid p2TG/flag.Hsp82wt serves to express Hsp82 with a FLAG epitope
at the N terminus. The expression vector was derived from
p2TG/hHsp90
. Sequences encoding the FLAG epitope (DYKDDDDK) were
placed between the initiator codon and the second codon of the
wild-type HSP82 sequences, following the introduction of a BglII site just upstream of the second nucleotide of the
HSP82-coding sequence. FLAG epitope and second amino acid of
Hsp82 are thus separated by the three extra amino acids EIL.
Other Plasmids.
Plasmid pYES/Ste11
N encoding Ste11
N
was generated as follows: the coding sequence for the catalytic domain
of Ste11 was excised from plasmid pNC199 (a gift from B. Errede) as a
DdeI-BglII fragment and subcloned into pSP72 to
add a BamHI site at the 5'-end. This fragment was further
subcloned as a BamHI-BglII fragment into a pUC18
derivative containing a stop codon in the proper reading frame followed
by a SacI site. Finally, the sequence encoding the catalytic
domain of Ste11 was introduced into plasmid pYES 2.0 (Invitrogen, San
Diego, CA) as a BamHI-SacI fragment. pYES 2.0 is
a yeast expression vector that contains the galactose-inducible GAL1 promoter, the 2µ replicon, and the URA3
selectable marker. Plasmid pYES/HA-Ste11 was constructed for
galactose-inducible expression of full-length Ste11 with an influenza
virus hemagglutinin (HA) epitope (Daro et al., 1996
)
at its N terminus; a KpnI-NdeI fragment with
sequences encoding the HA epitope (MQDLPGNDNSTAG) was joined in-frame
to a BamHI fragment carrying STE11-coding sequences from plasmid BB345 (mentioned as pYBS345 in Choi et al., 1994
) and cloned into pYES 2.0 linearized with
KpnI and NotI; noncomplementary sites were filled
in or chewed back to allow ligation.
N.GST served to express
glutathione-S-transferase (GST), GST fused to Ste5, and GST
fused to Ste11
N, respectively. p2U/GST-STE5 was constructed by
replacing the BamHI-BglII fragment at the 5'-end of HSP82 of p2U/Hsp82 with a BamHI fragment
carrying GST-coding sequences fused in-frame to STE5
sequences; STE5 sequences lacking the first 24 codons were
from plasmid BB192 (mentioned as pYBS146 in Choi et al.,
1994Strains
The parent strains and some of the derivatives are listed in
Table 2. The related yeast strain backgrounds, HH1a and JC6a (gifts
from S. Lindquist), were used to replace the endogenous Hsp82/Hsc82
with Hsp90 mutants by plasmid shuffling. Plasmids were introduced into
yeast by the LiAc/PEG method and selected for on appropriate minimal
media. Strain HH1a-pHCA/Hsp82wt is essentially the MATa
version of the previously described strain HH1-KAT6 (see Palmer
et al., 1995
). It was obtained by tetrad dissection of a
diploidized HH1-KAT6 and further plasmid shuffling.
The strain DP121 was obtained by substituting the HIS3
coding body for that of FUS1 in strain DP120 (see Table 2)
with the gene replacement construct pSL1497 (Stevenson et
al., 1992
). Plasmid p2U/Hsp82 was subsequently replaced by the
Hsp90 expression vectors pTCA/Hsp82, pTCA/Hsp82 G313N, and
p2TG/hHsp90
, to yield strains DP122, DP123, and DP124, respectively.
In strains HH1a-p2G/Hsp82wt, HH1a-p2G/Hsp82 G313N, and HH1a-p2G/hHsp90,
the Hsp90 derivatives themselves are used as selectable marker to
maintain the episomes.
-Factor Induction
To monitor the cell cycle arrest in response to
-factor,
cells were diluted to a density of 1.2 × 107 cells/ml
and streaked or spotted onto YEPD plates containing 10 mM Na-citrate,
pH 4.3, and, where indicated, 5 µM
-factor (Bachem, Torrance, CA).
The FUS1-LacZ reporter plasmid pSB234 was used to measure
the transcriptional output of the pheromone pathway (Trueheart et
al., 1987
). Wild-type and mutant strains were grown to early
logarithmic phase and exposed to 5 µM
-factor for 2 h after
addition of 10 mM Na-citrate, pH 4.3. Quantification of the LacZ
expression was performed as described by Yocum et al. (1984)
except that chlorophenol red-
-D-galactopyranoside was used as
-galactosidase substrate instead of
O-nitrophenyl
-D-galactopyranoside for
more sensitivity.
Rapid Protein Extraction
The levels of overexpressed Ste11 (yeast strains JC6a-Hsp82,
JC6a-Hsp82 G313N, and JC6a-hHsp90
with plasmid pYES/HA-Ste11) were
quantitated using crude extracts prepared by a rapid protein extraction
protocol (Horvath and Riezman, 1994
) and loaded onto 10%
SDS-polyacrylamide gels. To confirm that equal amounts of protein had
been loaded, proteins were stained with Ponceau S after transfer onto a
nitrocellulose membrane before immunostaining.
Analysis of Ste7 Phosphorylation
JC6a strains expressing the Hsp90 derivatives were transformed
with plasmid pUCA/Ste7 M. Transformants were grown to early logarithmic
phase in 1% sucrose as a carbon source. After addition of 10 mM
Na-citrate, pH 4.3, the cultures were exposed to 5 µM
-factor for
2 h. Cell extracts were prepared at 4°C by breaking the cells
with glass beads in 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM DTT, 20 mM
sodium molybdate, 15 mM MgCl2, 10% glycerol, 1 mM PMSF,
the protease inhibitors aprotinin, leupeptin, and pepstatin A, and the
phosphatase inhibitors okadaic acid (1 µM),
Na2MoO4 (10 mM), Na3VO4
(0.1 mM), and NaF (5 mM). Samples were frozen in liquid nitrogen and
stored at
70°C. Extracts, 10 µg each, as determined with the
Bio-Rad (Richmond, CA) Bradford reagent, were boiled in SDS sample
buffer for 5 min and loaded onto 7.5% SDS-polyacrylamide gels.
GST Pull-Down and Immunoprecipitation Experiments
GST pull-down experiments were performed as follows. Yeast cells
(strain RMY326 with plasmids pYes/Ste11
N.GST or p2U/GST-2) were
washed once with water containing 1 mM DTT and 1 mM PMSF and once with
TEG (25 mM Tris-HCl pH 7.4, 15 mM EGTA, 10% glycerol, 1 mM DTT, 1 mM
PMSF, 3 µg/ml chymostatin, 1.5 µg/ml pepstatin A, 0.75 µg/ml
leupeptin, 3.8 µg/ml antipain) containing 150 mM NaCl. Cell pellets
were then resuspended in a small volume of the same buffer and broken
with glass beads by two 30-s pulses at maximum speed in a
Mini-BeadBeater-8 (Biospec Products, Bartlesville, OK) at 4°C. After
centrifugation at 15,000 rpm in a table top centrifuge at 4°C, the
supernatant was quantitated and adjusted to 0.1% Triton X-100.
Glutathione-sepharose beads (Pharmacia, Piscataway, NJ) were added to
the extracts, tumbled for 30-45 min at 4°C, washed three times with
TEG containing 150 mM NaCl, 0.1% Triton X-100 and twice with TEG with
0.1% Triton X-100. Bound proteins were eluted with 7.5 mM reduced
glutathione in 50 mM Tris-HCl, pH 8.0, and concentrated by
trichloroacetic acid (TCA) precipitation, resuspended in SDS sample
buffer, and loaded onto 10% SDS-polyacrylamide gels.
Coimmunoprecipitation experiments using the FLAG tag were done as
follows. Extracts from strains HH1a-p2TG/flag.Hsp82wt and HH1a-p2G/hsp82wt with and without plasmid pYES/HA-Ste11 were prepared as described above for the GST pull-down experiments except that the
buffer was 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM DTT, 10 mM sodium
molybdate, 1 mM EDTA, 10% glycerol, 1 mM PMSF, 3 µg/ml chymostatin,
1.5 µg/ml pepstatin A, 0.75 µg/ml leupeptin, 3.8 µg/ml antipain.
After adjusting the extracts to 0.1% Triton X-100, they were incubated
at 4°C with the anti-FLAG monoclonal antibody M2 (Eastman Kodak,
Rochester, NY) for 2 h followed by 1 h with Protein
G-sepharose (Pharmacia). Immunoprecipitates were washed four times for
10 min at 4°C with the extraction buffer containing 0.1% Triton
X-100, solubilized in SDS sample buffer, and loaded onto 10%
SDS-polyacrylamide gels. The same protocol was used for immunoprecipitation by a Ste11-specific rabbit polyclonal antiserum (Cairns et al., 1992
) of endogenous Ste11 from 0.5 mg of
extracts from strains HH1a-p2G/Hsp82wt, HH1a-p2G/Hsp82 G313N, and
HH1a-p2G/hHsp90
.
Western Blot Experiments
After transfer of proteins from SDS-polyacrylamide gels to
nitrocellulose membranes, the membranes were blocked with Tris-buffered saline, 0.05% Tween-20 (TBST) containing 5% (wt/vol) milk powder and
probed with appropriate antibodies in TBST + milk powder at room
temperature for 1 h. Mouse anti-GST (Santa Cruz Biotechnology, Santa Cruz, CA), anti-HA (a gift from K. Matter; for references, see
Daro et al., 1996
), and anti-FLAG (Kodak) monoclonal
antibodies, chicken anti-Hsp82 antibodies (Louvion et al.,
1996
), rabbit polyclonal anti-Hsp82 antiserum (a gift from S. Lindquist), and rabbit polyclonal anti-Ste11 antiserum (Cairns et
al., 1992
) were diluted 1:1000, 1:100, and to 10 µg/ml, 1:1000,
1:400, and 1:1000, respectively. Membranes were washed three times for
10 min with TBST. The secondary antibodies were alkaline
phosphatase-conjugated goat anti-rabbit (Bio-Rad) or anti-chicken
(Promega, Madison, WI), horseradish peroxidase-conjugated anti-mouse
(Cappel, Cochranville, PA). They were used in TBST + milk powder at
room temperature for 1 h. After three washes with TBST, the blots
were developed either with the NBT/BCIP reagent for alkaline
phosphatase or with the enhanced chemiluminescence reagent (Amersham,
Arlington Heights, IL) for horseradish peroxidase.
| |
RESULTS |
|---|
|
|
|---|
HSP90 Mutations Interfere with Pheromone-induced Cell Cycle Arrest and Activation of FUS1 Promoter
A large variety of HSP90 mutants have been described
that complement yeast strains carrying disruptions of the essential
chromosomal HSP90 genes, HSP82 and
HSC82 (Borkovich et al., 1989
; Picard et al., 1990
; Bohen and Yamamoto, 1993
; Kimura et al.,
1994
; Minami et al., 1994
; Bohen, 1995
; Nathan and
Lindquist, 1995
; Palmer et al., 1995
; Louvion et
al., 1996
). We examined pheromone signaling (Figure
1A) in three types of mutant strains: a
strain with only 10% of the normal levels of Hsp82, a strain with
human Hsp90
(hHsp90
; hereafter considered a Hsp90 mutant for
yeast), and strains expressing specific Hsp82 point mutants. The latter
had been found in a screen for defective steroid receptor signaling in
yeast. The point mutants T525I and G313N are temperature sensitive for
viability and show an impaired hormonal response of glucocorticoid, estrogen, progesterone, and mineralocorticoid receptors (Bohen and
Yamamoto, 1993
; Bohen, 1995
). Hsp82 T525I and Hsp82 G313N are expressed
at similar levels as the wild-type Hsp82 (Bohen and Yamamoto, 1993
;
Bohen, 1995
) (see also Figure 4B). We first tested the different mutant
strains for their ability to arrest growth in response to the mating
pheromone
-factor. As shown in Figure 1B, low levels of Hsp82, point
mutant Hsp82 G313N, and hHsp90
are not able to promote a substantial
activation of the pheromone pathway as demonstrated by a poor growth
arrest in the presence of pheromone. Interestingly, the point mutation
T525I discriminates between two different functions of Hsp90, the
pheromone and the steroid-signaling pathways being functional and
defective, respectively. The other Hsp90 isoform of yeast, Hsc82, as
well as the Trypanosoma cruzi Hsp83, which we have
previously shown to complement defective yeast strains (Palmer et
al., 1995
), are also able to support pheromone signaling (our
unpublished results).
|
The activation of the pheromone pathway also results in the induction
of proteins required for cellular and nuclear fusion (mating). To test
the Hsp90 requirement in the pheromone-dependent transactivation of
mating genes such as FUS1, we assessed the induction of a
FUS1-LacZ reporter gene (Trueheart et
al., 1987
) upon treatment of cells with
-factor. The results
shown in Figure 1C indicate that, similarly to what was observed in the
case of the G1 arrest, the activation of
FUS1-LacZ in response to
-factor is strongly
reduced in Hsp90 mutant strains compared with a strain with wild-type Hsp82.
Basal Activity of the Pheromone-signaling Pathway Also Depends on Hsp90
The pheromone pathway exhibits low activity even in the absence of
pheromones (Hagen et al., 1991
). To determine whether Hsp90 is also required for this basal activity, we examined the activity of a
more sensitive reporter gene, FUS1-HIS3, in a
his3
strain. Any disruption in the pheromone
signaling pathway, such as the complete absence of a component,
abrogates the basal activity and prevents growth on medium lacking
histidine (Stevenson et al., 1992
). As shown in Figure
2, growth on selective medium is severely
impaired for Hsp82 G313N and hHsp90
strains when compared with a
strain with wild-type Hsp82. In this assay, the hHsp90
strain is
reproducibly the most defective. These results indicate that Hsp90 is
necessary for both the induced and the basal activity of the
pheromone-signaling pathway.
|
Hsp90 Mutants Block Signaling by Constitutive Ste11
In a first attempt toward determining the step(s) of the pheromone
pathway (Figure 1A) that is dependent on Hsp90, we assayed growth
arrest induced by a constitutively active Ste11 mutant. It has been
shown that the deletion of the amino-terminal regulatory domain of
Ste11 (Ste11
N) results in constitutive activation of this kinase and
in pheromone-independent induction of the mating pathway (Cairns
et al., 1992
). We constructed such a dominant STE11 and placed it under the control of the conditional
GAL1 promoter. When the expression is induced by growth on
galactose, only the strain with wild-type Hsp82 exhibits a complete
growth arrest (Figure 3A). Strains with
either Hsp82 G313N or hHsp90
fail to be fully growth arrested. The
same pattern was observed with equivalent strains of the opposite
mating type (MAT
) (our unpublished results). Thus, these
experiments showed that the requirement for Hsp90 is independent of
mating type and possibly at the level of Ste11 or downstream of it.
|
Ste5 Overexpression Suppresses the Signaling Defect
We performed a screen for high-copy suppressors of the signaling
defect of Hsp90 mutant strains. Using the hHsp90
strain with the
FUS1-HIS3 reporter, we selected suppressors that allow growth on plates lacking histidine in the absence of pheromone and
screened them further for a restored sensitivity to
-factor. In a
limited screen with a yeast genomic library in a high-copy vector, only
one clone met the two criteria. Sequencing revealed that its genomic
insert contains the STE5 gene. It starts 1020 bp upstream of
the initiator codon ATG and presumably contains the complete
STE5 promoter. At the 3'-end the STE5 sequence is truncated at codon 801 (of 917). The isolated plasmid, denoted Ste5
C, thus encodes the first 800 amino acids of Ste5 fused to 15 unrelated amino acids at the C terminus. Further experiments showed
that Ste5
C is also able to suppress the HSP82 mutation G313N. Figure 3B shows the growth assays on plates lacking histidine and also illustrates that full-length Ste5, as a fusion protein with
GST, retains suppressor activity. These data corroborate the tentative
conclusion that Hsp90 may be required at the level of the MAPK module
consisting of the kinases Ste11, Ste7, and Fus3 that are tethered
together by Ste5 (reviewed by Elion, 1995
; Leberer et al.,
1997
).
Ste11 Protein Levels Are Reduced
Certain client proteins of Hsp90, such as Raf-1, the
glucocorticoid receptor, or luciferase, appear more susceptible to
degradation when interaction with Hsp90 is blocked/altered
pharmacologically (Schulte et al., 1995
-1997
; Schneider
et al., 1996
; Whitesell and Cook, 1996
; Czar et
al., 1997
; Segnitz and Gehring, 1997
; Stancato et al.,
1997
). We therefore examined the accumulation of Ste11 in Hsp90 mutant
strains. An epitope-tagged version of Ste11 was overexpressed under the
control of the inducible GAL1 promoter and revealed by
immunoblotting (Figure
4A, left panel). In strains with
hHsp90
or Hsp82 G313N, Ste11 levels were severely reduced. In the
Hsp82 G313N strain Ste11 levels were at the detection limit. At this
point we speculated that the levels of the endogenous Ste11, which is
difficult to detect, might mirror this pattern. To explore this
possibility, we concentrated endogenous wild-type Ste11 by
immunoprecipitation with a Ste11-specific antiserum and displayed it by
immunoblotting with the same antiserum (Figure 4A,
right panel). Despite a relatively high background, the identity of the
Ste11 band could be confirmed unambiguously using an extract from a
ste11
strain as a control sample (Figure 4A,
lane
). As in the case of the overexpressed Ste11, accumulation of
endogenous Ste11 is reduced in both mutant strains although Hsp82 G313N
appears to have a less severe effect on the endogenous than on the
overexpressed protein. Thus, reduced levels of Ste11 could, at least in
part, explain the functional defects of the pheromone pathway in these strains.
|
Basal and Induced Phosphorylation of Ste7 Is Reduced
The direct target of the Ste11 kinase is the kinase Ste7 (Figure
1A). Upon exposure to pheromone, Ste7 is activated by phosphorylation by Ste11 and becomes hyperphosphorylated in the presence of Fus3/Kss1 (Zhou et al., 1993
; Neiman and Herskowitz, 1994
). As shown
in Figure 4B, the degree of hyperphosphorylation of Ste7 as well as
Ste7 protein levels is strongly reduced in mutant strains. The latter
is particularly true for Hsp82 G313N. When compared with the wild-type
strain, all the mutant strains show a three- to fivefold reduced
hyperphosphorylation of Ste7 both in the absence (basal activity) and
in the presence (induced activity) of pheromone. This experiment
indicates that Hsp90 function is essential both for Ste7 accumulation
and for efficient basal and induced phosphorylation of Ste7.
Ste11 Forms Complexes with Hsp90
Several experiments described so far suggested that Hsp90 might
interact with components of the MAPK module and Ste11 in particular. We
performed coprecipitation experiments to examine this issue. Figure
5A shows that HA epitope-tagged Ste11 is
specifically coprecipitated with FLAG-tagged Hsp82. The association of
Ste11 and yeast Hsp90 (Hsp82) was confirmed by a GST pull-down
experiment. GST alone or GST fused to the constitutive Ste11
N
(Ste11
N.GST) was inducibly expressed under the GAL1
promoter in a wild-type strain. While wild-type Hsp82 (and Hsc82) does
not associate with GST alone, it specifically coprecipitates with
Ste11
N.GST (Figure 5B). These results establish that Ste11 exists in
complexes with Hsp90 and that the regulatory N-terminal domain of Ste11
is dispensable for this interaction.
|
Differential Temperature Sensitivity of Hsp90 Mutants
Surprisingly, the Hsp82 requirement for pheromone signaling
exhibits a temperature dependence. The mutant phenotype of Hsp82 G313N
and hHsp90
strains was not apparent in all assays at the lower
temperature of 21°C (Table
1). This is
particularly striking for G313N whose response in all our assays is
only slightly reduced compared with wild-type Hsp82 at 21°C. In
contrast, low amounts of wild-type Hsp82 are unable to support
signaling in response to
-factor even at the lower temperature.
Similarly, the basal and
-factor-induced activities of the
pheromone pathway are defective in strains with hHsp90
at both
temperatures. Interestingly, a full growth arrest is observed at 21°C
with a hHsp90
strain when the pheromone pathway is activated with
the constitutive Ste11
N. This suggests that Hsp90 function might be
required differentially both "upstream" and "downstream" of
Ste11. At low temperature, hHsp90
appears to be able to fulfill the
downstream, but not the upstream requirement. Since none of the
mutations are able to block the Ste11
N-induced cell cycle arrest at
the lower temperature, we cannot formally rule out the possibility that
Hsp90 function is not required at all for this particular response.
However, this seems unlikely in view of the striking signaling defects at 30°C and may be due to the vast overexpression of Ste11
N in this assay and initiation of signaling at an intermediate level.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Using a series of Hsp90 mutants we have demonstrated that
pheromone signaling through the MAPK cascade depends on Hsp90 function. Hsp90 is required both for the basal activity of this pathway in the
absence of pheromone and for efficient induction upon exposure to
pheromone. A combination of genetic and biochemical experiments pinpoints Ste11, a yeast equivalent of Raf, as a target of Hsp90. Since
mammalian Raf-1 can substitute for Ste11 under certain circumstances (Freed et al., 1994
; Irie et al., 1994
), our
results also set the stage for using yeast genetics to investigate the
role of Hsp90 for Raf function and for mammalian MAPK signaling.
Ste11 Depends on Hsp90 Function
Our results support the conclusion that pheromone signaling
depends on Hsp90 at the level of Ste11: 1) The constitutive Ste11 mutant (Ste11
N) fails to elicit a complete cell cycle arrest (at
30°C) in Hsp90 mutant strains; 2) The levels of both endogenous and
overexpressed Ste11 are reduced in mutant strains; 3) The basal and
induced phosphorylation of the Ste11 substrate Ste7 are reduced in
mutant strains; 4) Ste11 and Hsp90 (Hsp82) are found in a complex.
The reduction of Ste11 protein levels are an indication that Hsp90 may
be required to ensure the stability of Ste11. Since the plasmids that
we used for overexpression of Ste11 contained exclusively the
STE11 coding body, the rate of synthesis is likely to be
similar. This leads to the tentative conclusion that it is the turnover
of Ste11 that is increased in Hsp90 mutant strains. Whether the
destabilization of Ste11 is due to misfolding and/or a failure to form
complexes with other factors remains to be determined. While the
effects on Ste11 protein levels could also be indirect, the finding
that Hsp90 and Ste11 form complexes suggests that it is the altered
nature of these complexes in Hsp90 mutant strains that leads to
enhanced degradation of Ste11. The low levels of Ste11 in these strains
have so far precluded experiments to determine whether Hsp90 mutants
form complexes with Ste11 at all. In vitro experiments with purified
components might allow assessment of whether the Ste11-Hsp90
interaction is direct and how it is affected by alterations of Hsp90.
Further analyses will also have to establish the stoichiometry of the
complex and the proportion of Ste11 that is associated with Hsp90 at
any given time. Interestingly, the effects of mutating HSP90
in yeast are mirrored by pharmacological experiments with the Hsp90
"drug" geldanamycin (or herbimycin A, another ansamycin) in
vertebrate cells. Raf-1 is degraded when cells are treated with this
compound (Schulte et al., 1995
-1997
; Schneider et
al., 1996
; Stancato et al., 1997
). Similar effects have
been reported for the glucocorticoid receptor, another Hsp90 substrate
(Whitesell and Cook, 1996
; Czar et al., 1997
; Segnitz and
Gehring, 1997
). Although accumulation of Raf was apparently not
affected in Drosophila strains with HSP83
mutations (van der Straten et al., 1997
), it should be
pointed out that the severity of the effect also depends on the
mutation in our system. Recently, Errede and her collaborators have
obtained results that support our conclusions. They could notably
demonstrate with a temperature-sensitive Hsp82 mutant (Nathan and
Lindquist, 1995
) that the accumulation of newly synthesized Ste11
depends on continuous Hsp90 function (Buehrer, Rhodes, Rutherford, and
Errede, unpublished data).
The reduced accumulation of Ste11 (and possibly Ste7) might be
sufficient to account for the mutant phenotype. Since it is technically
difficult to measure the specific activity of Ste11, we cannot exclude
that Ste11 also requires Hsp90 to reach its full enzymatic activity.
The residual number of Ste11 molecules in Hsp90 mutant strains might
well be sufficient, but they may have a lower specific activity. In the
case of geldanamycin-treated vertebrate cells, specific activity of Raf
appears to remain unchanged (Stancato et al., 1997
) whereas
in Drosophila its specific activity appeared to be affected
by HSP83 mutations (van der Straten et al.,
1997
).
The Hsp90 mutant strains that we have tested are not completely defective in Ste11 activity. Unlike ste11 deletion strains, they are able to form shmoos in response to pheromone, and they can mate albeit with reduced efficiency (our unpublished results). The hyperphosphorylation of Ste7 that occurs at a lower level even in Hsp90 mutant strains further corroborates that there is residual Ste11 activity. This is either due to a pathway that allows Ste11 maturation/stabilization to proceed partially in an Hsp90-independent manner or to residual activity of our panel of Hsp90 mutants. Indeed, Hsp90 mutants that are both viable and completely defective for this specific function may be difficult to find. Along with the fact that there are two genes for Hsp90 in S. cerevisiae, this residual Ste11 activity probably explains why HSP90 was never found in screens for sterile mutants.
Is Ste11 the Only Substrate of Hsp90 in the Pheromone-signaling Pathway?
Both biochemical evidence and results obtained with the yeast
two-hybrid system have led to the view that Ste11, Ste7, Fus3/Kss1, and
other components of the pheromone pathway are all tethered together by
Ste5. Ste5 may serve as a scaffold to maintain the different kinases
and their substrates in a macromolecular signal transduction complex,
thereby ensuring specificity and efficiency (for reviews, see Elion,
1995
; Leberer et al., 1997
). This illustrates that the
notion of a linear signal transduction from upstream to downstream
components, as derived from genetic epistasis experiments, is too
simplistic. Moreover, it does not take into account that additional
factors such as molecular chaperones could be required for the
maturation of the individual components and/or the multiprotein complex. Two linked hypotheses are worth considering in this context: 1) Hsp90 chaperones the dynamic assembly of this multiprotein signaling
complex; 2) Hsp90 is required for the maturation/stabilization of
additional signaling molecules. Note that Hsp90 does not have to be a
stable component of these complexes; it might only transiently interact
with Ste11 and/or other proteins.
To address the first hypothesis the tools have yet to be developed. Using the yeast two-hybrid assay that relies on interactions of chimeras in the nucleus, we have not seen any differences in Hsp90 mutant strains for the interactions of Ste5 with Ste11 or Ste7 (our unpublished results). However, it will ultimately be necessary to characterize the complex formed of the endogenous wild-type proteins, a technically daunting task.
Regarding the second hypothesis, the reduced Ste7 levels are
compatible, but not more, with an interaction of Ste7 with
Hsp90. The differential behavior of certain Hsp90 mutants, notably
hHsp90
, at different temperatures in different assays (see Table 1)
might also support such an assumption. While hHsp90
allows signaling by the constitutive Ste11
N at low temperature, it fails to allow pheromone to signal through the complete pathway. Interestingly, Ste5
overexpression suppresses the signaling defect of Hsp90 mutant strains,
but only biochemical experiments will be able to elucidate how this
increases the efficiency of the signaling complex. Taking these
observations as guidelines, the interaction of Hsp90 with signaling
molecules both upstream and downstream of Ste11 as well as Ste5 will
have to be examined directly.
Hsp90 Requirement in Other MAPK Pathways
Other MAPK-signaling pathways in yeast may also depend on Hsp90.
While the cell wall integrity pathway does not appear to be affected in
our Hsp90 mutant strains (our unpublished results), other pathways
await examination. This will be particularly interesting for the three
other pathways that are known to share Ste11: one of the two
osmoregulatory pathways (Posas and Saito, 1997
), the invasive growth
response of haploid cells, and pseudohyphal development of diploids
(see Herskowitz, 1995
; Levin and Errede, 1995
; Schultz et
al., 1995
). In this context it is noteworthy that the growth arrest/"toxicity" induced by Ste11
N appears to be due to its functions in both the pheromone and the high osmolarity response pathways (Posas and Saito, 1997
). Since Hsp90 mutant strains are at
least partially refractory to the Ste11
N toxicity, we speculate that
Hsp90 may be required for Ste11 function in both pathways.
Genetic Dissection of Different Hsp90 Functions
Previous studies had demonstrated that it is possible to
selectively abolish specific dispensable functions of Hsp90 without compromising its ability to ensure viability in yeast; specifically, a
variety of HSP82 mutations result in a defect in the
regulation of steroid receptors or v-Src or folding of p53 in yeast
(Picard et al., 1990
; Bohen and Yamamoto, 1993
; Xu and
Lindquist, 1993
; Bohen, 1995
; Nathan and Lindquist, 1995
; Blagosklonny
et al., 1996
; Fang et al., 1996
; Nathan et
al., 1997
). We have now considerably extended this theme by
showing that even subtle point mutations can discriminate between the
Hsp90 requirements in two different signaling pathways. Some mutants,
like the Hsp82 point mutant G313N, are defective in both steroid
receptor and pheromone signaling. Another point mutant, T525I, is only
defective in steroid receptor signaling while the converse is true for
human Hsp90 (this article and our unpublished results). Moreover, G313N
has a different temperature sensitivity for several Hsp90 functions: at
room temperature, only hormone binding of steroid receptors is
defective (Bohen, 1995
) whereas viability (Bohen and Yamamoto, 1993
)
and pheromone signaling are only lost upon increasing the temperature
to 37°C and 30°C, respectively. A deletion analysis of
HSP82 has proven of limited use in assigning specific
functions to individual domains of Hsp90 (Louvion et al.,
1996
). Only two regions, the eukaryote-specific N-terminal charged
domain and the C-terminal conserved pentapetide, could be deleted
without affecting viability. These two portions of Hsp82 are also
dispensable for Hsp90 function in pheromone signaling (Louvion et
al., 1996
). By ensuring viability with human Hsp90 (hHsp90
),
which cannot promote pheromone signaling, it might nevertheless be
possible to map the domains of Hsp82 that are specifically required for
its function in pheromone signaling. In such a system, even coexpressed
Hsp82 mutants, which fail to provide the viability function, might be
able to restore pheromone signaling. Additional insights could be
gained by examining a series of chimeras between yeast Hsp82 and human
Hsp90
.
| |
ACKNOWLEDGMENTS |
|---|
We thank S.P. Bohen and K.R. Yamamoto, B. Cairns, M. Collart, E.A. Elion, B. Errede, G.R. Fink, T. Kreis, S. Lindquist, K. Matter, R. Movva, G. Sprague, and D.O. Toft for plasmids, strains, antibodies, and other reagents. We acknowledge the sequencing services of S. Antonorakis and of the Department of Molecular Biology. We are grateful to M. Strubin and J. Geiselmann for critical comments on an early version of the manuscript. We thank B. Errede for her thoughtful comments and for communicating unpublished results. This work was supported by the Swiss National Science Foundation and the Canton de Genève.
| |
FOOTNOTES |
|---|
* These authors contributed equally to this work.
| |
ABBREVIATIONS |
|---|
Abbreviations used: HBD, hormone-binding domain; Hsp, heat-shock protein.
| |
REFERENCES |
|---|
|
|
|---|
implications for heat shock in vivo.
J. Biol. Chem.
270, 7288-7294